Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025

Merck’s Keytruda (pembrolizumab) remained pharma’s No. 1 brand in FY2025 with $31.7 billion in sales. But it is no longer the industry’s top-selling medicine at the molecule level. Lilly’s tirzepatide franchise, spanning Mounjaro ($22.965 billion) and Zepbound ($13.542 billion), reached roughly $36.5 billion in 2025 revenue, while Novo Nordisk’s semaglutide franchise, counting Ozempic, Wegovy and… The post Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025 appeared first on Drug Discovery and Development.

Continue reading →